Antiplatelet Therapy For High Bleeding Risk Patients Undergoing PCI
DAPT after PCI improves morbidity and mortality by reducing ischemic events but increases bleeding risk, especially for high bleeding risk patients. Nearly one-third of patients treated with PCI are considered to be at high bleeding risk, but these patients are frequently excluded from stent trials.
In a recent Cardiology article, Mohsin Chowdhury, MD, provides a brief primer on the use of antiplatelet therapy in high bleeding risk patients undergoing PCI in light of emerging data in this area. Read more.